Therapeutics Startups

Gilgamesh Pharmaceutical develops novel chemical entities for psychiatric disorders using medicinal chemistry and AI-powered translational platforms to design rapid-acting therapies targeting neurobiological mechanisms rather than symptom management. The company's pipeline spans depression, anxiety, addiction, and schizophrenia, with programs validated by AbbVie's acquisition of its first asset and partnerships with Columbia University and the National Institute on Drug Abuse.

19 investors

CatenaBio develops precision conjugation technology using native amino acids to enable biotherapeutic fusions of small molecules, nucleic acids, enzymes, and cells. The company partners with pharmaceutical firms to advance development of novel therapeutic modalities.

11 investors

Kopra Bio develops cancer immunotherapy technology that converts cancer cells into biofactories to produce their own destruction. The company operates in the biotech and cancer treatment space.

10 investors

ParcelBio develops APEXm, a proprietary mRNA platform that enhances protein expression for longer-lasting therapeutic effect compared to conventional mRNA technologies. The platform targets autoimmune disease, oncology, and therapeutic protein replacement applications.

10 investors

Abalone Bio develops activating antibodies (agonists) targeting hard-to-drug receptors such as G-protein coupled receptors, using engineered cells to measure antibody pharmacological activity at high throughput combined with machine learning. Its initial focus is cell-specific antibody drugs for obesity and metabolic disease aimed at avoiding the GI side effects associated with GLP-1 therapies.

9 investors

EngageBio develops DNA-based medicines using proprietary non-viral delivery technology to achieve extended therapeutic expression from a single dose with low manufacturing complexity.

9 investors

Sensible Biotechnologies develops a cell-based mRNA design and manufacturing platform that produces pure, low immunogenicity mRNA therapeutics for drug development. The platform addresses limitations of synthetic mRNA by enabling design-based biology approaches.

9 investors

Valink Therapeutics develops bispecific antibody-drug conjugates (ADCs) for therapeutic applications, combining high-throughput discovery, antibody engineering, and medicinal chemistry capabilities.

9 investors

Altay Therapeutics develops small molecule inhibitors targeting transcription factors to treat serious diseases including facioscapulohumeral muscular dystrophy and cancer. The company's pipeline includes oral drug candidates designed as first- or best-in-class therapeutics for oncology and inflammatory conditions.

7 investors

FinalDose develops a programmable DNA-targeting molecule designed to recognize and destroy cells carrying specific genetic sequences, with initial applications in oncology across cancer types.

7 investors

Persist AI provides AI-driven formulation development services for pharmaceutical compounds, combining robotic lab automation with machine learning models to accelerate drug formulation optimization and reduce time-to-market.

7 investors

Velorium develops transformational medicines by combining scientific research with patient-focused collaboration. The company operates in the medical research and therapeutic development space.

7 investors

Equator Therapeutics develops first-in-class drugs targeting mitochondrial thermogenesis to treat obesity and metabolic disorders by restoring the body's natural heat production mechanism. The company uses bioelectricity research and high-throughput assays to identify selective activators of thermogenic compounds in mitochondria.

6 investors

Granza Bio develops immunotherapy treatments leveraging naturally-occurring attack particles that are released from cytotoxic immune cells to target diseases including cancers, autoimmunity, and infections.

6 investors

Promakhos Therapeutics develops immunomodulatory therapies to restore immune system balance and reduce chronic inflammation in diseases like Crohn's disease, ankylosing spondylitis, and psoriasis. The company targets patients with inflammatory diseases who do not benefit from current immunosuppressive treatments.

6 investors

Sequence Bio works on drug target discovery, using the Newfoundland founder effect to identify genetic signals of disease and improve the success rate of drug development.

6 investors

Serinus Biosciences uses AI and systems biology to design drug combinations that overcome cancer cells' resistance to existing treatments, targeting safer and more effective therapeutic options.

6 investors

Yemaachi creates a diverse cancer bio-database to develop oncology drugs effective across diverse patient populations. The company develops precision oncology research, diagnostics, and therapeutics with a focus on inclusion for global communities.

6 investors

Algen Biotechnologies discovers and develops small molecule therapeutics for cancer and inflammatory diseases using CRISPR, RNAi, and machine learning to decode functional gene networks and predict drug responses.

5 investors

Alixia develops therapeutics targeting tumor ecosystems to address cancer drug resistance and age-related diseases. The company integrates biology, biophysics, and computational chemistry to design compounds that disrupt metabolic and inflammatory triggers in multiple cell types within the tumor microenvironment.

5 investors

Gerostate Alpha develops therapeutics aimed at aging and chronic disease. The company operates in the biotech and therapeutics space.

4 investors

Matrubials develops antimicrobial peptides derived from milk to create novel therapeutics for bacterial infections, starting with bacterial vaginosis. The company uses AI-enabled technology to identify and validate bioactive molecules for infectious disease treatments.

4 investors

RonanRx offers personalized GLP-1 weight-management care delivered via text, where a licensed physician reviews a patient's history to set an individualized dose, titration schedule, and patient-specific adjunct, and a licensed pharmacist at the patient's selected pharmacy verifies and releases compounded, patient-specific prescriptions. It serves individual patients in the US (availability varies by state) and plans to add hormone therapy (HRT).

4 investors

SafeBeat uses engineering and machine learning to develop solutions for cardiac care and arrhythmia management. The company serves cardiologists, electrophysiologists, and healthcare organizations.

4 investors